SEC Form 8-K Summary
Registrant: Deep Medicine Acquisition Corp. (the request identifies TruGolf Holdings, Inc., but the filing names Deep Medicine Acquisition Corp.)
Report date: July 11, 2023; signed July 12, 2023. The company is a special purpose acquisition company and had not yet completed an initial business combination.
Material Agreement and Transaction Status
- The company and Bright Vision Sponsor LLC entered into non-redemption agreements with unaffiliated investors in connection with a proposed extension of the deadline to complete an initial business combination.
- The extension would move the deadline from July 29, 2023 to January 29, 2024, subject to stockholder approval at a special meeting.
- As of the report date, agreements covered up to 22,606 non-redeemed Class A shares. The sponsor agreed to transfer up to 8,138 founder shares to participating investors after a business combination, provided they continue to hold the non-redeemed shares through the special meeting.
- The company expected to enter into additional non-redemption agreements before the special meeting. These agreements were intended to increase funds remaining in the trust account, not to materially increase the likelihood that the extension proposal would be approved.
Financial Metrics and Liquidity
- As of July 11, 2023, the company had received redemption requests for 465,446 Class A common shares.
- 4,147,964 Class A shares remained non-redeemed, including 364,764 shares initially sold as part of the IPO units.
- The estimated pro rata trust-account value available for redemption as of July 29, 2023 was approximately $11.45 per share, subject to future deductions, tax withholdings and accrued interest.
- The filing does not provide revenue, profit, operating cash flow, margins, debt balances or other conventional operating-company financial metrics.
- Trust-account funds were to remain invested in short-term U.S. government securities, qualifying government money market funds or cash in an interest-bearing demand deposit account until a business combination or liquidation.
- The company agreed that trust-account funds, including interest, would not be used to pay excise-tax liabilities relating to future redemptions before or in connection with the extension, a business combination or liquidation.
Changes, Outlook and Risks
- The principal change was the proposed extension of the business-combination deadline and the related non-redemption arrangements.
- Stockholders could withdraw redemption requests until 5:00 p.m. Eastern Time on July 13, 2023.
- There was no assurance that stockholders would approve the extension, that the company would enter into a definitive business-combination agreement, or that any proposed transaction would close on acceptable terms.
- Completion of a business combination remained subject to uncertainty, including financing, transaction terms, redemptions and other factors described in the company’s SEC filings.
- The filing included customary forward-looking-statement disclaimers and stated that the company had no obligation to update such statements except as required by law.
Investor Verification Checklist
- Verify the outcome of the special meeting and whether the extension to January 29, 2024 was approved.
- Verify final redemption levels, remaining public shares and the final per-share trust-account balance.
- Review the executed non-redemption agreements and the potential transfer of up to 8,138 founder shares.
- Confirm whether the company subsequently announced a definitive business combination, liquidation or further deadline extension.
- Review the company’s proxy statement and subsequent SEC filings for updated trust-account, tax, redemption and transaction information.